DE60119285D1 - Verwendung von plgf zur vorbeugung oder behandlung von ischaemie oder schlaganfall - Google Patents
Verwendung von plgf zur vorbeugung oder behandlung von ischaemie oder schlaganfallInfo
- Publication number
- DE60119285D1 DE60119285D1 DE60119285T DE60119285T DE60119285D1 DE 60119285 D1 DE60119285 D1 DE 60119285D1 DE 60119285 T DE60119285 T DE 60119285T DE 60119285 T DE60119285 T DE 60119285T DE 60119285 D1 DE60119285 D1 DE 60119285D1
- Authority
- DE
- Germany
- Prior art keywords
- ischaemie
- plgf
- hitch
- treat
- prevent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1891—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Vascular Medicine (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pressure Vessels And Lids Thereof (AREA)
- Dowels (AREA)
- Clamps And Clips (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0002527A GB0002527D0 (en) | 2000-02-04 | 2000-02-04 | Use of vascular endothelial growth factor (VEGF) placental growth factor (PLGF)or both for the treatment of ischemic and acute myocardial infaction |
GB0002527 | 2000-02-04 | ||
US23659400P | 2000-09-29 | 2000-09-29 | |
US236594P | 2000-09-29 | ||
PCT/EP2001/001208 WO2001056593A2 (en) | 2000-02-04 | 2001-02-05 | Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60119285D1 true DE60119285D1 (de) | 2006-06-08 |
DE60119285T2 DE60119285T2 (de) | 2007-05-10 |
Family
ID=26243563
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60119285T Expired - Lifetime DE60119285T2 (de) | 2000-02-04 | 2001-02-05 | Verwendung von plgf zur vorbeugung oder behandlung von ischaemie oder schlaganfall |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1253935B1 (de) |
JP (1) | JP4969753B2 (de) |
AT (1) | ATE324905T1 (de) |
AU (2) | AU4643501A (de) |
DE (1) | DE60119285T2 (de) |
DK (1) | DK1253935T3 (de) |
ES (1) | ES2263582T3 (de) |
PT (1) | PT1253935E (de) |
WO (2) | WO2001057181A2 (de) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2405291A1 (en) * | 2000-04-06 | 2001-10-18 | Wayne P. Franco | Methods of using growth factors for treating heart disease |
CA2454251A1 (en) * | 2001-08-10 | 2003-02-20 | Imclone Systems Incorporated | Isolation and mobilization of stem cells expressing vegfr-1 |
ITRM20020119A1 (it) * | 2002-03-05 | 2003-09-05 | Geymonat Spa | Composizioni contenenti plgf ad uso farmaceutico e cosmetico. |
US8409815B2 (en) | 2002-11-16 | 2013-04-02 | Siemens Healthcare Diagnostics Products Gmbh | sCD40L and placental growth factor (PLGF) used as a biochemical marker combination in cardiovascular diseases |
EP2295449A1 (de) | 2009-09-09 | 2011-03-16 | Dompe PHA.R.MA S.p.A. | PLGF-1 in homodimerer Form |
US10729746B2 (en) * | 2013-01-28 | 2020-08-04 | Shire Human Genetic Therapies, Inc. | Recombinant placenta growth factor for treating Duchenne muscular dystrophy |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6121246A (en) * | 1995-10-20 | 2000-09-19 | St. Elizabeth's Medical Center Of Boston, Inc. | Method for treating ischemic tissue |
ES2251740T3 (es) * | 1996-08-23 | 2006-05-01 | Ludwig Institute For Cancer Research | Factor de crecimiento de celulas de endotelio vascular d recombinante (vegf-d). |
NZ514872A (en) * | 1997-04-25 | 2005-01-28 | Collateral Therapeutics | Truncated VEGF-B, VRF-2, VEGF-C, PlGF, VEGF-3, poxvirus ORF-1 and poxvirus ORF-2 proteins |
GB2332373A (en) * | 1997-12-19 | 1999-06-23 | Merck & Co Inc | Treatment of coronary and/or peripheral ischemia using an antithrombotic agent and an angiogenesis promoter |
SG117417A1 (en) * | 1998-02-06 | 2005-12-29 | Collateral Therpeutics Inc | Variants of the angiogenic factor vascular endothelial cell growth factor: vegf |
-
2001
- 2001-02-02 WO PCT/EP2001/001659 patent/WO2001057181A2/en unknown
- 2001-02-02 AU AU46435/01A patent/AU4643501A/en not_active Withdrawn
- 2001-02-05 WO PCT/EP2001/001208 patent/WO2001056593A2/en active IP Right Grant
- 2001-02-05 EP EP01902406A patent/EP1253935B1/de not_active Expired - Lifetime
- 2001-02-05 JP JP2001556492A patent/JP4969753B2/ja not_active Expired - Fee Related
- 2001-02-05 AT AT01902406T patent/ATE324905T1/de active
- 2001-02-05 DE DE60119285T patent/DE60119285T2/de not_active Expired - Lifetime
- 2001-02-05 ES ES01902406T patent/ES2263582T3/es not_active Expired - Lifetime
- 2001-02-05 PT PT01902406T patent/PT1253935E/pt unknown
- 2001-02-05 AU AU2001230243A patent/AU2001230243A1/en not_active Abandoned
- 2001-02-05 DK DK01902406T patent/DK1253935T3/da active
Also Published As
Publication number | Publication date |
---|---|
WO2001057181A2 (en) | 2001-08-09 |
ATE324905T1 (de) | 2006-06-15 |
ES2263582T3 (es) | 2006-12-16 |
AU4643501A (en) | 2001-08-14 |
WO2001056593A3 (en) | 2002-04-25 |
EP1253935B1 (de) | 2006-05-03 |
PT1253935E (pt) | 2006-08-31 |
DK1253935T3 (da) | 2006-09-04 |
DE60119285T2 (de) | 2007-05-10 |
WO2001056593A2 (en) | 2001-08-09 |
JP2003521522A (ja) | 2003-07-15 |
EP1253935A2 (de) | 2002-11-06 |
AU2001230243A1 (en) | 2001-08-14 |
JP4969753B2 (ja) | 2012-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE489957T1 (de) | Mittel zur behandlung von entzündlichen erkrankungen | |
ATE303156T1 (de) | Verwendung von gnrh-analogue zur behandlung der harninkontinenz | |
MEP8209A (en) | Modified factor viii | |
AR023130A1 (es) | Composiciones para promover el crecimiento | |
ATE468137T1 (de) | Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten | |
DE69925024D1 (de) | Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten | |
DE602005026866D1 (de) | Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen | |
DE60101265D1 (de) | Behandlung von augenschmerzen | |
ATE415962T1 (de) | Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs | |
HK1205531A1 (en) | Mesenchymal stem cells and uses therefor | |
ATE332705T1 (de) | Verwendung von in der mittlere oder späte follikuläre phase verabreichte lh zur behandlung von anovulatorischen frauen | |
DE60206289D1 (de) | Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne | |
ATE418552T1 (de) | Substituierte amino-furan-2-yl-essigsaure- und amino-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz | |
DE60119285D1 (de) | Verwendung von plgf zur vorbeugung oder behandlung von ischaemie oder schlaganfall | |
TR200200278T2 (tr) | Kalsilitik bileşimler | |
NO20026286D0 (no) | Nye peptider | |
DE69818809D1 (de) | Verfahren zur behandlung von narbengewebe | |
DE602004019541D1 (de) | Cycloalkyläbü kondensierte indole | |
ATE320255T1 (de) | Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen | |
ATE300944T1 (de) | Verwendung von substituierten distamycin- acryloylderivaten zur behandlung von tumoren die mit erhöhten glutathion-spiegeln zusammenhängen | |
ATE236633T1 (de) | Topische verwendung von loperamid zur behandlung mikrobieller infektionen | |
DE60109594D1 (de) | R-eliprodil zur behandlung von glaucoma | |
ATE222501T1 (de) | Tissue-faktor zur beeinflussung von gefässbildung | |
ATE343387T1 (de) | S-methyl-dihydro-ziprasidon zur behandlung von augenerkrankungen. | |
DE60128084D1 (de) | Verwendung von inaktives cln2 proenzym zur behandlung von lincl |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |